Sector News

Sanofi in talks with Actelion, sources say

December 14, 2016
Life sciences

French pharmaceutical company Sanofi is in talks with Swiss drugmaker Actelion, but a deal is not imminent, sources confirmed to CNBC on Wednesday.

U.S. shares of Actelion and Sanofi were down 9 percent and 2.5 percent, respectively, on Wednesday.

It’s unclear what price Sanofi might pay or what structure is envisioned, but the deal could value Actelion as much as $30 billion, according to The Wall Street Journal, which first reported on the talks and cited people familiar with the matter.

On Tuesday, Johnson & Johnson ended its discussions with Actelion regarding a possible transaction. Actelion told J&J it was confident it could attract a higher offer than the 250 Swiss francs per share the U.S. company had offered, Reuters reported.

In August, Sanofi, eager for deals to broaden its drug lineup, was trumped by Pfizer’s $14 billion bid for U.S. cancer drug company Medivation.

Source: CNBC

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.